Bladder cancer is one of the most common causes of death in industrialized countries. New tumor markers and therapeutic approaches are still needed to improve the management of bladder cancer patients. Choline kinase-a (ChoKa) is a metabolic enzyme that has a role in cell proliferation and transformation. Inhibitors of ChoKa show antitumoral activity and are expected to be introduced soon in clinical trials. This study aims to assess whether ChoKa plays a role in the aggressiveness of bladder tumors and constitutes a new approach for bladder cancer treatment. We show here that ChoKa is constitutively altered in human bladder tumor cells. Furthermore, in vivo murine models, including an orthotopic model to mimic as much as possible the physiological conditions, revealed that increased levels of ChoKa potentiate both tumor formation (Pp0.0001) and aggressiveness of the disease on different end points (P ¼ 0.011). Accordingly, increased levels of ChoKa significantly reduce survival of mice with bladder cancer (P ¼ 0.05). Finally, treatment with a ChoKa-specific inhibitor resulted in a significant inhibition of tumor growth (P ¼ 0.02) and in a relevant increase in survival (P ¼ 0.03).
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Introduction
Bladder cancer is the fifth leading cause of cancer in industrialized countries and one of the most expensive for health care systems (Jemal et al., 2007) . At diagnosis, most of the patients (70-75%) with urothelial bladder carcinoma present with superficial tumors, 20% show muscle-invasive tumors and only around 5% show metastatic tumors. However, more than 50% of these initially superficial tumors will eventually recur (Sanderson et al., 2007) .
Experimental and clinical evidence indicate that urothelial carcinomas arise and progress through at least two independent mechanisms that result in two different molecular and phenotypic versions with different prognosis (Wu, 2005) . In addition, several markers have been evaluated as potential tools for risk estimation of tumor progression with promising results (Cordon-Cardo et al., 1997; Hernando et al., 2001; Lu et al., 2002; Quek et al., 2005; Wu, 2005) . Beyond the clinicopathological factors, molecular features associated with a greater risk of disease progression have been found, such as multiple aneuploid cells, nuclear p53 overexpression and expression of the Lewis x blood group antigen (Wu, 2005) . However, the biology of bladder carcinoma is highly complex, still resulting in an almost unpredictable clinical behavior. Thus, additional markers for more accurate patient classification, diagnosis and prognosis are still needed for better management of bladder cancer.
Choline kinase (ChoK) is a metabolic enzyme responsible for the generation of phosphorylcholine (PCho) in eukaryotic cells. In mammals, two different proteins have been identified, ChoKa and ChoKb, encoded by two different genes located at 11q13 and 22q13 loci, respectively (Aoyama et al., 2004) . In the past few years, it has been found that besides its structural function, the a-isoform (ChoKa) is closely related to the regulation of cell growth, playing a relevant role in cell transformation and in the carcinogenic process (Nakagami et al., 1999; Lacal, 2001; Ramirez de Molina et al., 2002a, b; 2005) . Furthermore, a recent study performed in early-stage non-small cell lung cancer patients points at ChoKa as a new relevant factor useful to identify patients with poor prognosis that could be susceptible to a different strategy of treatment (Ramirez de Molina et al., 2007) . By contrast, recent evidence shows that ChoKb is not able to induce cell transformation because of a differential behavior in phospholipids metabolism under in vivo conditions (Gallego-Ortega et al., 2009) . Finally, specific inhibitors of ChoKa have been generated with proven antiproliferative and antitumoral activity both in vitro and in vivo, and they are expected to be introduced soon in clinical trials (Hernandez-Alcoceba et al., 1997 Lacal, 2001; Rodriguez-Gonzalez et al., 2003 , 2005 Ramirez de Molina et al., 2004; Al-Saffar et al., 2006; Gallego-Ortega et al., 2009) . Furthermore, it has been shown that the specific ChoKa inhibitor MN58b shows a dramatically differential effect on tumoral cells, which die by apoptosis, with respect to the equivalent normal cells that are reversibly arrested at G 0 /G 1 phase of the cell cycle, because of a differential mechanism of action involving ceramide production (Rodriguez-Gonzalez et al., 2003 , 2005 Al-Saffar et al., 2006) .
In this report, we analyse whether ChoKa activation contributes to the initiation and progression of bladder cancer both in vitro and in vivo. Experimental evidence presented here suggests that this lipid-related kinase is actually an important regulator of the pathogenesis of bladder cancer.
Results

Human bladder cancer cell lines show constitutive ChoKa activation
To analyse the relevance of ChoKa in bladder tumorigenesis, the expression and activity of this enzyme were assessed in a panel of human bladder cancer cell lines compared with non-transformed immortalized urothelial cells (UROTsa). As shown in Figure 1a , all tumoral cells show increased levels of ChoKa expression and activity with both of them oscillating between 3.6-and 15-fold with respect to control UROTsa cells. It is noted that an excellent correlation between the number of mRNA copies, protein expression levels and choline kinase enzymatic activity was observed.
The results shown above indicate that ChoKa is constitutively overexpressed in human bladder cancer cells. To analyse whether these tumoral cells might be appropriate candidates for an antitumoral treatment based on ChoKa inhibition, the effects of MN58b were assayed in human bladder cancer cells compared with control UROTsa cells. As shown in Figure 1b ChoKa overexpression potentiates the tumorigenic properties of human bladder cancer cells With the aim of analysing whether ChoKa overexpression modulates the incidence and/or aggressiveness of bladder tumors, and to verify the hypothesis of ChoKa as a new therapeutic target in bladder cancer, several in vivo experiments were carried out. To that end, human bladder cancer-derived SW780 cells were stably transfected with an expression vector encoding ChoKa (SW780_ChoK), or with the pCDNA empty vector as control (SW780_pCDNA), and the functional overexpression of ChoKa in these cells was verified (Figure 2a) . The effects of ChoKa on the oncogenic behavior of human SW780 bladder tumor cells were analysed by two alternative methods. First, cells transfected either with the empty vector or with the vector encoding for ChoKa were plated on soft agar in the presence or absence of MN58b. As shown in Figure 2b , ChoKa overexpression efficiently enhanced the transforming properties of SW780 bladder cancer cells as determined by the number of colonies. Moreover, the addition of MN58b completely abrogated the anchorage-independent growth ability of these cells.
In addition, 24 mice were subcutaneously injected with SW780-pCDNA and another 24 with SW780_ChoK, and tumor growth was monitored every 3 days. Initially, although control SW780_pCDNA cells induced detectable tumors only in a small percentage of recipient animals (29%), SW780_ChoK cells developed tumors in almost all of the injected mice (83%) approximately 10-15 days after injection (Pp0.0001; Table 1 ). Furthermore, both the tumor volume and growth rate of SW780_ChoK cells were statistically significantly higher (P ¼ 0.011) than that displayed by SW780_pCDNA-derived tumors (Figure 2c ). In addition, the overall tumor incidence at the end of the experiment (47 days after implantation) was statistically significantly higher for ChoKa-overexpressing cells (P ¼ 0.023) than that observed for control cells (Table 1) . Accordingly, a complete necropsy of four mice from each group was performed, and retroperitoneal lymph node metastasis was found in only one ChoK-overexpressing mouse (data not shown). Finally, to verify that this oncogene was determinant for the enhanced tumorigenic behavior of these cells, ChoKa overexpression was confirmed in the generated tumors (Figure 2c ). These results suggest that ChoKa overexpression in human bladder cancer cells potentiates both tumor formation and aggressiveness.
Next, the sensitivity to ChoKa inhibition was also determined by treatment with MN58b. When tumors reached a mean volume of 0.05-0.1 cm 3 , mice were randomized in treated (intraperitoneally (i.p.) injected with MN58b; 5 mg/kg) or control groups (injected with vehicle). In keeping with previous results, a significant decrease (P ¼ 0.02) of 65.1% in tumor growth was observed on SW780_pCDNA-injected mice on treatment with this ChoKa-specific inhibitor ( Figure 2d ). Furthermore, this effect was more noticeable in mice inoculated with ChoKa-overexpressing cells (P ¼ 0.019), with 77% of tumor growth inhibition. (Kikuchi et al., 2004; Mullerad et al., 2005) . MBT-2 (murine bladder tumor) is a well-established model for in vivo experimental analysis of urothelial carcinoma in immunocompetent mice (Oliveira et al., 2006) . Therefore, an orthotopic bladder cancer model of ChoKa overexpression was set up to provide definitive evidence for a role of ChoKa in bladder tumorigenesis. In addition, the effectiveness of an anti-bladder cancer therapy based on ChoKaspecific inhibition has also been evaluated under conditions that mimic the physiological process. To verify whether the MBT-2 model was comparable with that of human SW780 bladder cancer cells, some preliminary experiments were carried out. First, we determined whether MBT-2 cells showed increased levels of ChoKa expression and activity when compared with non-transformed murine fibroblasts NIH3T3 ( Figure 3a ). In addition, the effect of MN58b on the oncogenic behavior of MBT-2 was also analysed by anchorage-independent growth observing that, as expected, the addition of MN58b completely abrogated their ability to form colonies in soft agar (data not shown). Furthermore, 40 mice were injected subcutaneously with MBT-2 cells, and once the tumor volume reached 0.1 cm 3 , 20 of them were kept as controls and the remaining 20 mice were treated intraperitoneally with MN58b. As shown in the figure, treatment with MN58b resulted in a statistically significant inhibition of tumor growth (77.6%; Pp0.0001).
The effect of ChoKa on the establishment of orthotopic bladder tumors, as well as the in vivo response of these tumors to ChoKa inhibition, was next investigated in an orthotopic model. MBT-2 cells were permanently transduced either with a retroviral vector encoding for human ChoKa or with the corresponding empty vector (PIG) as control (Figure 3b) , and after antibiotic selection they were inoculated transurethrally directly into the mouse bladder. Five days after instillation, every set of mice (PIG and ChoKa) was randomly separated into two groups, and treated or not with MN58b.
The feasibility of magnetic resonance imaging (MRI) for detection of early-stage orthotopic MBT-2 implants has been shown earlier (Chin et al., 1991; Kikuchi et al., 2003) . This method provides an effective non-invasive system for the early detection and exact measurement of the tumors generated. Twenty days after instillation, mice were monitored by MRI to obtain images of the generated tumors. A representative picture of the observed images is shown in Figure 3b . The mean tumor size of tumors found at that time in the control mice was 0.55 cm 3 , whereas for ChoKa-overexpressing tumors it was 0.82 cm 3 , 50% bigger. Moreover, some of the ChoKa-overexpressing tumors reached volumes that made them protrude outside of the bladder (Figure 3c ). In addition, when comparing the mortality rate at 28 days after instillation, it was statistically significantly higher (P ¼ 0.031) for those mice with ChoKa overexpression (Table 2) . Furthermore, at the end point of the experiment, the presence of established MBT-2 intravesical tumors was confirmed by gross pathology. The histological examination revealed a higher incidence of kidney lesions (indicative of tumor dissemination) in mice with ChoKa overexpression (Table 2) . To verify whether ChoK activation was present all over the process, ChoK activity was analysed in all of the extracted tumors at the end of the experiment (Figure 3c ). MBT-2-induced tumors showed a constitutive increase in the basal levels of ChoK activity when compared with normal tissues, which was significantly higher in tumors generated by ChoKa-overexpressing cells. Histological analysis of orthotopic tumors was also performed, revealing an increased number of mitotic figures in ChoKa-overexpressing than in vector-transduced MBT-2 tumors (Figure 3d ). Consequently, all the ChoKa-mediated effects resulted, even in this particularly fast and aggressive bladder cancer model, in a significantly worse outcome of mice overexpressing this oncogene, as can be observed in Figure 4a (P ¼ 0.05). Thus, although median survival time of control mice was 32 days, this was reduced in ChoKa-overexpressing mice to 22 days, a 36% reduction. Finally, the in vivo response of MBT-2 tumors to ChoKa inhibition was also evaluated in this orthotopic model. According to the results shown above, ChoKaoverexpressing tumors were more sensitive to the antitumoral effect of MN58b. In this group, the mean tumor size of treated tumors was significantly reduced from 0.82 to 0.22 cm 3 and, importantly, the tumor incidence was also reduced in 43% in treated mice with respect to control (Table 2) . Furthermore, generated tumors showed a retardation in tumor growth that resulted in increased median survival time from 34 to 42 days in mice inoculated with MBT-2 vectortransduced cells, more apparent in MBT-2 cells overexpressing ChoKa (from 22 to 40 days; P ¼ 0.03; Figure 4b ). Overall, these results are indicative of a remarkable oncogenic effect of ChoKa in the bladder.
Discussion
ChoKa has been recently described as a novel human oncogene with clinical relevance as a prognostic factor in early-stage non-small cell lung cancer (Ramirez de Molina et al., , 2007 Glunde and Bhujwalla, 2007) . in vivo effect of ChoKa overexpression in human bladder tumor cells. The results indicate that ChoKa not only contributes to transformation but also promotes tumor progression because increased ChoKa activity in the tumor also significantly enhances the aggressiveness of the disease. Finally, to provide definitive evidence of the involvement of ChoKa in the genesis and progression of bladder cancer, an orthotopic model was developed that was non-invasively monitored by MRI. Regardless of the intrinsic accelerated evolution of the MBT-2 orthotopic model, ChoKa overexpression was able to increase tumor size by 50% and dissemination to the kidney by 200%. In addition, early mortality rate was significantly affected by the overexpression of this oncogene, resulting in a significantly worse overall outcome. These results strongly show for the first time that ChoKa is indeed a relevant molecule in bladder carcinogenesis and that it is involved in tumor generation, progression and disease outcome. As ChoKa plays an important role in bladder tumor generation and evolution, the specific inhibition of this enzyme was evaluated as a potential novel antitumoral strategy against bladder cancer. To that end, we used MN58b, a highly selective ChoKa inhibitor (Hernandez-Alcoceba et al., 1997 Rodriguez-Gonzalez et al., 2003 , 2005 Choline kinase-a in human bladder cancer E Hernando et al undergo massive apoptosis after MN58b treatment, an effect that has been evaluated in three different cell lines: SW780 (Figure 2b and c), J82 and UMUC3 (data not shown). By contrast, non-transformed bladder cells remain arrested in the G 1 phase of the cell cycle, revealing the potential of ChoKa inhibition as a specific therapeutic strategy against bladder cancer. In addition, the inhibition of ChoKa showed an efficient antitumoral activity against human bladder cancer xenografts. Finally, when analysing the in vivo response to ChoKa inhibition in a more physiological orthotopic model, a remarkable inhibition of tumor growth was noticed resulting in increased overall survival. Consistently, ChoKa-overexpressing tumors were more sensitive to the antitumoral effect of MN58b, and tumor incidence was also reduced in this group by 43% in treated mice with respect to control. Thus, as only tumor cells die by apoptosis after MN58b treatment, and ChoKa inhibition has an efficient in vivo effect against bladder cancer, a new antitumoral therapy based on ChoKa inhibition seems an optimal approach for treatment of bladder cancer patients. The exquisite dependence of certain tumors for a specific catalytic activity or pathway for survival, named 'oncogene addiction,' has been recently exploited for targeted therapy (Jonkers and Berns, 2004; Garraway and Sellers, 2006; Weinstein and Joe, 2006) . The strict dependence of bladder cancer cells for ChoKa activity unravels a new therapeutically appealing molecular target for treatment of these tumors. Urothelial carcinoma is one of the most common cancers worldwide. The current elevated morbidity associated to bladder cancer demands a better knowledge of the molecular mechanisms underlying bladder tumorigenesis and progression. Furthermore, new molecular biomarkers are needed for a more accurate patient classification and diagnosis of bladder cancer patients that allows a rational application of multimodality strategies that improve overall survival. Among the genetic alterations that characterize urothelial tumorigenesis, defects of chromosome 11, where ChoKa is localized, are frequent and have been often associated with tumor progression and invasiveness (Cordon-Cardo et al., 1997). Thus, though further studies are needed to determine the mechanism of ChoKa upregulation in bladder cancer, the results shown here demonstrate that this enzyme displays a significant role in the development and invasive behavior of these tumors and point out at this oncogene as a target for future studies focused on determining its relevance as a putative marker and therapeutic target for bladder cancer patients. MBT-2/PIG/MN58b 9 7 (77%) 1 (14.3%) MBT-2/ChoK/MN58b 8 3 (37,5%) 0 (0%)
Abbreviations: ChoK, choline kinase; MBT, murine bladder tumor. Choline kinase-a in human bladder cancer E Hernando et al
Materials and methods
Cell culture and transfections
All the cell lines used in this study were maintained under standard conditions of temperature (37 1C), humidity (95%) and carbon dioxide (5%). Human non-transformed UROTsa and human bladder tumoral cells (ATCC, LGC Standards, Barcelona, Spain) were maintained in MEM (Gibco reference 31095-029) supplemented with non-essential amino acids (Gibco reference 11140), 200 mM glutamine (Gibco reference 25030) and 10% fetal bovine serum (FBS; Gibco reference 10106-169). Murine MBT-2 were grown in RPMI supplemented with 10% FBS and NIH3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% newborn calf serum. Stable transfection of human SW780 cells was carried out using the Lipofectamine Plus Reagent from Gibco BRL (distributed by Invitrogen, Barcelona, Spain) as described by the manufacturers, and 48 h posttransfection selection with gentamicine was added. Human ChoKa cDNA was also subcloned into the retroviral vector MSCV-PIG. MBT-2 cells were transduced by three rounds of infection with fresh retroviral supernatants from MSCV or MSCV-Choka-transfected ecothropic Phoenix cells, filtered through 0.45 mm and supplemented with polybrene (4 ug/ml). Transduced cells were selected 48 h postinfection by adding puromycine (2 mg/ml).
Analysis of protein levels by western blotting
Cells were lysed in ice-cold lysis buffer (50 mM Tris, pH 7.4, 0.25% NP-40, 0.25% SDS, 150 mM NaCl, 15 mM b-glycerophosphate, 10 mM Na PPi, 50 mM NaF, 10 mg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride). Nuclei and detergentinsoluble material were removed by centrifugation at 13 000 r.p.m. for 20 min at 4 1C. Western blot analysis of equal amounts of cell lysates (30 mg) was performed using each correspondent antibody. ChoKa monoclonal antibody was obtained as described in 26. When analysing ChoKa expression in murine cells, a monoclonal antibody against this enzyme recognizing human and murine ChoK was used (Gallego-Ortega et al., 2006) . Antibodies against PARP (SC-7150), tubulin (T9026) and actin (A2066) were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA) and Sigma (St Louis, MO, USA), respectively.
Choline kinase enzymatic assays Choline kinase enzymatic assays were performed with cell extracts in buffer containing 100 mM Tris-HCl pH 8.0, 100 mM MgCl2 and 10 mM adenosinetriphosphate, using as substrate the physiological choline concentration (200 mM) in the presence of methyl[ 14 C]-choline chloride (50-60 mCi/mmol; Amersham International, Didcot, UK). Reactions were performed at 37 1C for 30 min and stopped with ice-cold trichloracetic acid at a final concentration of 16%. After washing with water-saturated ethylether, samples were lyophilysed. Hydrophilic derivatives of choline were resolved in TLC plates (60 A silica gel; Whatman, Clifton, NJ, USA), using as liquid phase 0.9% NaCl/methanol/ammonium hydroxide (50:70:5; V/V/V). Radioactivity/radioactive signal corresponding to PCho was automatically quantified by an electronic radiography system (Instantimager; Packard, Meriden, CT, USA).
Flow cytometry analysis
When indicated, cells were treated for 48 h with MN58b (25 mM), and flow cytometry analysis was carried out. To that end, cells were trypsinized, centrifuged and diluted in 1 ml phosphate-buffered saline (PBS), and 9 ml of ethanol 70% were added while vortexing. After 24 h at À20 1C, cells were washed with PBS and resuspended in 1 ml of PBS buffer containing 2.5 mM C 6 H 5 Na 3 O 7 , 0,01% TX 100 and 20 mg propidium iodide. FACScan analysis for relative DNA content based on fluorescence was carried out. Cell-cycle analysis was then performed by flow cytometry using a commercially available software package FACs SCAN Beckton Dickinson (Franklin Lakes, NJ, USA).
Anchorage-independent growth in soft agar Anchorage-independent growth assay was performed as described earlier by plating 50 000 cells/60-mm dish. Five days after the cells were seeded, a few drops of new fresh media with or without the presence of MN58b (25 mM) were added every three days. After 5 weeks of incubation, the medium was absorbed, 500 ml of 0.005% crystal violet was added and incubated for 1 h at 37 1C. Plates were then washed once with 1 Â PBS and visualized under a microscope.
In vivo subcutaneous tumorigenic assay and ChoKa inhibitor treatment Indicated cells were resuspended in DMEM just before inoculation (10 6 cells/0.1 ml), and injected subcutaneously in nu/nu immunosuppressed mice. Mice were kept in pathogenfree housing under the guidelines of the Spanish and MSKCC institutional Animal Care and Use Committee and Research Animal Resource Center. When tumors reached a mean volume of 0.1 cm 3 , mice were randomized to control and treated groups. Treatment with MN58b (and vehicle for control mice) was performed i.p. with a schedule of daily consecutive doses of 5 mg/kg for 5 days, with a 9-day interval. Tumors were monitored at least twice a week by measuring the major (D) and minor (d) diameters, and tumor volume was calculated by
In vivo orthotopic model Experiments were approved by the Institutional Animal Care and Use Committee of Memorial Sloan-Kettering Cancer Center. Eight-week-old female C3H/HeJ mice (Jackson Laboratory, Bar Harbor, ME, USA) were maintained in pathogen-free, isolated barrier facilities. For tumor implantation, animals were anesthetized with an intraperitoneal injection of ketamine (Fort Dodge Animal Health, Fort Dodge, IA, USA; 100 mg/kg) and xylazine (Lloyd Laboratories, Shenandoah, IA, USA; 20 mg/kg). A 22-gauge catheter was inserted into the bladder transurethrally and the urethra was temporarily ligated with a 3-zero silk suture that was maintained for 3 h. Subsequently, 2 Â 10 6 MBT-2 cells transduced either with empty PIG vector or vector encoding for ChoKa were instilled directly into the bladder.
Histopathological analysis
During the necropsy of the animals, a tissue portion was snap frozen in liquid nitrogen to assess ChoKa levels. Another piece of tumor and kidney tissues was formalin fixed and embedded in paraffin for histological analyses.
Magnetic resonance imaging
All MR images were acquired on a Bruker 4.7T Biospec scanner (Bruker Biospin Inc., Billerica, MA, USA) with a console running ParaVision 3.0. A 32 mm quadrature birdcage volume coil (Stark Contrast MRI Coils Research, Erlangen, Germany) was used for signal detection in all measurements. The animals were catheterized under anesthesia with 1.5% isofluorane and their bladders were emptied and then injected with a contrast medium comprising 50% Magnevist (Berlex, Montville, NJ, USA) and 50% air. The animals were kept under anesthesia during MR scan. Initial scout images along the three orthogonal orientations were acquired using a fast-spin-echo (RARE) sequence to locate the bladder position. A T-weighted spin-echo method (MSME) was used for bladder imaging, with a 301 flip angle, TR ¼ 211 ms, TE ¼ 5.5 ms and NEX ¼ 8. The axial image slice thickness is 1 mm with a 0.3 mm gap, FOV of 30 Â 25 mm and an in-plane resolution of 117 Â 130 mm. The imaging time for the axial scan is 5 min. Image postprocessing was carried out using the Xtip graphics software suite on a Linux workstation (Bruker Biospin MRI, Erlangen, Germany). For each slice, the tumor outline was manually traced and the area computed. The tumor volume was calculated from the sum of all the areas of the tumor and multiplied by the total slice separation.
Statistical analysis
The Kaplan-Meier method was used to estimate bladder cancer-specific survival. The univariate association between ChoKa expression and tumor behavior was analysed using Fisher's exact test. Continuous variables with non-normal distribution were compared by using Kruskal-Wallis and Mann-Whitney U-tests and those with normal distribution were compared by means of Student's t-test. All reported P values are two sided. Statistical significance was defined as Po0.05. The statistical analyses were performed using SPSS software, version 13.0 (SPSS Inc., Chicago, IL, USA).
